Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19
P. Clot (Chilly-Mazarin, France), C. Farenc (Montpellier, France), B. Suratt (Cambridge, United States of America), T. Krahnke (Frankfurt, Germany), A. Tardat (Montpellier, Germany), P. Florian (Frankfurt, Germany), R. Pomponio (Framingham, United States of America), N. Patel (Cambridge, United States of America), M. Wiekowski (Bridgewater, United States of America), Y. Lin (Bridgewater, United States of America), B. Terrier (Paris, France), H. Staudinger (Bridgewater, United States of America)
Source: Virtual Congress 2021 – Back to infection basics
Session: Back to infection basics
Session type: E-poster
Number: 2363
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Clot (Chilly-Mazarin, France), C. Farenc (Montpellier, France), B. Suratt (Cambridge, United States of America), T. Krahnke (Frankfurt, Germany), A. Tardat (Montpellier, Germany), P. Florian (Frankfurt, Germany), R. Pomponio (Framingham, United States of America), N. Patel (Cambridge, United States of America), M. Wiekowski (Bridgewater, United States of America), Y. Lin (Bridgewater, United States of America), B. Terrier (Paris, France), H. Staudinger (Bridgewater, United States of America). Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19. 2363
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: